16.07.2010 • News

J&J Revamping Tylenol Plant, Slashing Jobs There

Johnson & Johnson on Thursday said it aims to revamp a now-closed Pennsylvania plant that made Tylenol and other consumer medicines that have been recalled in recent months due to quality-control lapses and eliminate 300 of the factory's more than 400 employees.

J&J said other company plants will help produce medicines once made at the factory as it is retrofitted, and reaffirmed that most of the products are unlikely to become available before the end of 2010.

The company, in a statement, also said it earlier on Thursday had given the U.S. Food and Drug Administration an expected "comprehensive action plan" that listed other proposed means of correcting quality shortcomings at its factories. They have led to four major recalls of J&J consumer medicines in the past year that have tarnished the reputation of the company and its iconic brands.

The company said its McNeil Consumer Healthcare unit had already begun taking a number of significant steps to enhance quality controls, and will use outside experts to go further. One of the biggest recalls came on April 30, when J&J took 40 widely used children's medications off the market, including painkillers Tylenol and Motrin and allergy treatments Benadryl and Zyrtec.

The plant in Fort Washington, Pa. was closed after FDA inspectors said they found thick dust, grime and contaminated ingredients in the facility.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.